William Sandborn, MD

Jessica Allegretti, MD, MPH, and Edward Loftus Jr., MD, review emerging agents in the later phases for the management of IBD.

William Sandborn, MD, discusses various novel agents being investigated for the management of IBD.

Expert gastroenterologists review the unmet needs in IBD management.

Details of the head-to-head SEAVUE study of ustekinumab vs adalimumab for induction and maintenance therapy in patients with moderate to severe Crohn disease.

Edward Loftus Jr, MD, and William Sandborn, MD, review the 5-year remission data from the IM-UNITI trial for ustekinumab and post hoc analysis from the GEMINI 2 trial for vedolizumab in patients with Crohn disease.

A panel of experts share their experiences with the use of biologics for the treatment of inflammatory bowel diseases (IBDs).

Indications for surgery in treating patients for ulcerative colitis (UC) and Crohn disease.

Expert gastroenterologists share their perspectives regarding overall treatment approach in a patient with moderate- to high-risk inflammatory bowel disease.

Initial IBD therapy for a patient with low-risk disease and measuring treatment response on initial therapy.

Important patient factors to consider other than severity of disease when choosing a therapeutic agent for inflammatory bowel disease.

A panel of experts discuss the latest guidelines and how they make a treatment decision for patients with ulcerative colitis and Crohn’s disease.

Panel of gastroenterologists share their perspectives regarding the diagnostic work-up for patients who may have symptoms suggestive of IBD.

Expert opinions on the effect of the progressive, relapsing nature of inflammatory bowel disease on a patients’ quality of life.

Effect of age, gender, racial, and socioeconomic disparities on the incidence and prevalence of inflammatory bowel disease (IBD).

Expert gastroenterologists review the pathophysiology of inflammatory bowel disease (IBD) along with the associated risk factors.